The PTC Therapeutics symposium at MDA 2023 focused on all-around care for Duchenne muscular dystrophy (DMD). This symposium detailed how corticosteroids can be integrated into all-around DMD care
The PTC Therapeutics symposium at MDA 2023 focused on all-around care for Duchenne muscular dystrophy (DMD). This infographic, distributed during the symposium, provides a summary of how corticosteroids can be integrated into all-around DMD care
This poster, presented at MDA 2023, provides an overview of a phase 3 placebo-controlled trial assessing the motor function of patients with nonsense mutation Duchenne muscular dystrophy (nmDMD) treated with ataluren
This poster, presented at MDA 2023, assesses the efficacy of ataluren on muscle function in patients with nonsense mutation Duchenne muscular dystrophy (nmDMD) over 3 trials
This poster, presented at MDA 2023, provides an overview of a phase 3 trial assessing the effects of ataluren on muscle burst activity in patients with nonsense mutation Duchenne muscular dystrophy (nmDMD)
This poster, presented at WMS 2022, focuses on the safety and efficacy results of Study 041, a phase 3 placebo-controlled trial of ataluren for patients with nonsense mutation Duchenne muscular dystrophy (nmDMD)
This poster, presented at WMS 2022, shows findings from a registry study investigating the effects of a mutation-specific treatment for nonsense mutation Duchenne muscular dystrophy (nmDMD) on upper limb function
The best practice management and continuity of care in patients with Duchenne muscular dystrophy (DMD) was the focus of this symposium, presented at WMS 2022
This poster, presented at the 2022 14th EPNS Congress in Glasgow, discusses the functional outcomes of patients with nonsense mutation Duchenne muscular dystrophy (nmDMD) receiving a mutation-specific DMD therapy in real-world practice versus a clinical trial setting
View an analysis of motor function in patients with nonsense mutation Duchenne muscular dystrophy (nmDMD) receiving ataluren in real-world practice versus a clinical trial setting in our poster presented at EPNS 2022
Presented at the 2022 AAN Annual Meeting in Seattle, USA, this poster shows results from a study investigating disease progression following treatment with different corticosteroids for Duchenne muscular dystrophy (DMD)
This poster, presented at the 2022 AAN Annual Meeting in Seattle, USA, presents the results of a comparison of corticosteroid treatments in non-ambulatory patients with DMD
View the key takeaways from our MDA 2022 Virtual Industry Forum, which summarizes the role of corticosteroids in the treatment of patients with Duchenne muscular dystrophy (DMD)
Watch our hybrid Industry Forum at MDA 2022, which discusses the latest clinical findings on the role of corticosteroid treatment in the management of Duchenne muscular dystrophy (DMD)
This poster, from the 2022 MDA Conference in Nashville, Tennessee, USA, presents the ambulatory outcomes observed following treatment for nonsense mutation Duchenne muscular dystrophy (nmDMD) in the STRIDE Registry and Study 020, a Phase 3 clinical trial
This poster, presented at the 2022 MDA Conference in Nashville, Tennessee, USA, reports the results of a comparison of corticosteroid treatments on clinical outcomes in non-ambulatory DMD patients
This poster from the 2022 MDA Conference in Nashville, Tennessee, USA, presents results from a study comparing clinical outcomes in patients with Duchenne muscular dystrophy (DMD) by corticosteroid type within distinct patient subgroups
This poster, presented at the 2022 MDA Conference in Nashville, Tennessee, USA, shows the results of a study comparing 2 corticosteroids in delaying disease progression milestones in patients with DMD
This poster, presented at the 2022 MDA Conference in Nashville, Tennessee, USA, shows results from a propensity score-matched registry analysis, using data from the STRIDE Registry and CINRG Natural History Study, to determine the effect of a mutation-specific treatment for nonsense mutation Duchenne muscular dystrophy (nmDMD) on pulmonary function
This poster, from the 2022 MDA Conference in Nashville, Tennessee, USA, compares the age at loss of ambulation in patients with nonsense mutation Duchenne muscular dystrophy (nmDMD) enrolled in the STRIDE Registry and CINRG Natural History Study
This poster, presented at the 2022 MDA Conference in Nashville, Tennessee, USA, provides safety data from a registry analysis of boys with nonsense-mutation Duchenne muscular dystrophy (nmDMD)
Watch our virtual symposium at ICNMD 2020, which discusses long-term real-world evidence (RWE) regarding ataluren use in patients with nonsense mutation DMD (nmDMD)
Year
Therapy area
Congress
Type
Topic
Access PTC abstracts, infographics, posters and symposia presented at international meetings in the fields of pediatric neurology, cognitive neuroscience and movement disorders, such as the Muscular Dystrophy Association (MDA) Annual Clinical & Scientific Conference, the Child Neurological Society (CNS) Annual Meeting, the World Muscle Society (WMS) Annual Congress, and the European Paediatric Neurology Society (EPNS) Congress.